Exjade and Hypertensive crisis - a phase IV clinical study of FDA data

Among these 13 people:

How long have people been on Exjade when they have Hypertensive crisis? *

• < 1 month: 100 %
• 1 - 6 months: 0.0 %
• 6 - 12 months: 0.0 %
• 1 - 2 years: 0.0 %
• 2 - 5 years: 0.0 %
• 5 - 10 years: 0.0 %
• 10+ years: 0.0 %

What is the gender of people who have Hypertensive crisis when taking Exjade? *

• female: 36.36 %
• male: 63.64 %

What is the age of people who have Hypertensive crisis when taking Exjade? *

• 0-1: 0.0 %
• 2-9: 18.18 %
• 10-19: 36.36 %
• 20-29: 0.0 %
• 30-39: 0.0 %
• 40-49: 0.0 %
• 50-59: 9.09 %
• 60+: 36.36 %

What are other drugs people take besides Exjade? *

1. Pantoprazole: 5 people, 38.46%
2. Metformin: 3 people, 23.08%
3. Vfend: 3 people, 23.08%
4. Mcp: 3 people, 23.08%
5. Vidaza: 3 people, 23.08%
6. Aspirin: 1 person, 7.69%
7. Calcium: 1 person, 7.69%
8. Diovan: 1 person, 7.69%
9. Doxazosin Mesylate: 1 person, 7.69%
10. Humalog: 1 person, 7.69%

What are other side effects people have besides Hypertensive crisis? *

1. Dyspnea (difficult or laboured breathing): 4 people, 30.77%
2. Urinary Tract Infection: 3 people, 23.08%
3. Angiodysplasia (small vascular malformation of the gut): 3 people, 23.08%
4. Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 3 people, 23.08%
5. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 3 people, 23.08%
6. Cough: 3 people, 23.08%
7. Diarrhea: 3 people, 23.08%
8. Haematemesis (vomiting of blood): 3 people, 23.08%
9. Hepatitis (inflammation of the liver): 2 people, 15.38%
10. Concomitant Disease Aggravated (advanced due to some of accompanying): 2 people, 15.38%

What are the existing conditions these people have? *

1. High Blood Pressure: 7 people, 53.85%
2. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 4 people, 30.77%
3. Type 2 Diabetes: 3 people, 23.08%
4. Thyroid Diseases: 3 people, 23.08%
5. Haematemesis (vomiting of blood): 3 people, 23.08%
6. Dyspnea (difficult or laboured breathing): 3 people, 23.08%
7. Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 7.69%
8. Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 1 person, 7.69%
9. Osteoporosis (bones weak and more likely to break): 1 person, 7.69%
10. Iron Metabolism Disorder: 1 person, 7.69%

Do you take Exjade and have Hypertensive crisis?

- Check whether Hypertensive crisis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

---

---

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Exjade:

Hypertensive crisis treatments and more:

How severe was Hypertensive crisis and when was it recovered:

• Hypertensive crisis in Exjade

Expand to all the drugs that have ingredients of deferasirox:

• Hypertensive crisis and drugs with ingredients of deferasirox

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Exjade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

• Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
• Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
• Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
• Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
• Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
• Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
• Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
• Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
• Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
• Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .

---

How the study uses the data?

The study uses data from the FDA. It is based on deferasirox (the active ingredients of Exjade) and Exjade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

---

---

Recent studies on eHealthMe:

• Atrovent and Anxiety, Apprehension, Feeling Uptight, Jitters, Stress, Stress And Anxiety, Tension for Women aged 30-39 - now
• Atrovent and Jitters for Women aged 30-39 - a second ago
• Atrovent and Feeling Uptight for Women aged 30-39 - 2 seconds ago
• Atrovent and Apprehension for Women aged 30-39 - 2 seconds ago
• Atrovent and Anxiety for Women aged 30-39 - 2 seconds ago
• Atrovent and Anxiolytic Therapy for Women aged 30-39 - 3 seconds ago
• Spinal Column Stenosis and Urinary Tract Infection - 3 seconds ago
• Drug interactions of Revlimid and Hydroxyzine Hydrochloride - 3 seconds ago
• Drug interactions of Colace and Carbidopa, Levodopa And Entacapone - 5 seconds ago
• Drug interactions of Epoprostenol and Magnesium Sulfate - 12 seconds ago